Though earnings were strong in the third quarter, Bristol-Myers Squibb Co. used its Oct. 27 sales and earnings call to reassure investors about cost control going forward, with CEO Giovanni Caforio outlining an operating model transformation for the pharma that would keep operating costs level from 2016 to 2020.
Bristol reported third quarter worldwide sales of $4.9bn, up an impressive 21% year-over-year, including 36% revenue growth domestically to $2.8bn....








